富血小板纤维蛋白联合自体骨髓浓缩物修复骨缺损的早期疗效

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (1362 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：通过动物实验评价富血小板纤维蛋白（PRF）联合自体骨髓浓缩物（BMAC）修复骨缺损的早期效果。方法：12～16月龄日本大耳白兔6只，于颅顶制备4个直径为5 mm的圆形骨缺损，随机填入空白（A组）、自体骨沫（B组）、PRF与BMAC混合物（C组），并对PRF行组织学分析。术后6周取材，通过影像学检查及组织学分析评价骨缺损的修复效果。结果：PRF为乳白色纤维蛋白凝胶，具有弹性和韧性，组织学切片可见疏松多孔的网状胶原纤维，基底部网络少量白细胞。各组骨缺损均未见炎症反应，新骨生成率分别为：A组（7.64±1.02）%，B组（12.94±0.81）%，C组（37.19±1.26）%，C组新骨生成率显著高于A、B组（P＜0.05）。结论：PRF联合BMAC可以显著加快新骨再生的速度，促进兔颅骨缺损的修复。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨颖
	刘国
	刘传通
	金琼
	朱飞

关键词 ：富血小板纤维蛋白, 自体骨髓浓缩物, 骨再生

Abstract：Objective: To assess the initial effects of platelet-rich fibrin (PRF) in conjunction with bone marrow aspirate concentrate (BMAC) on reconstruction of bone defect. Methods: Four bone defects of 5-mm in diameter were performed in the calvaria of 6 rabbits. These defects were randomly filled with blood clot (group A), autogenous bone (group B), PRF and BMAC (group C). Meanwhile, PRF was collected for histological observation. Animals were sacrificed 6 weeks later, and bone samples were harvested for histological observation and statistical analysis. Results: PRF was milk white fibrin glue with elasticity and toughness. The loose and porous three dimensional network structure and white blood cells at the bottom of PRF could be seen in the histological sections. The percentage of new bone formed in each group was 7.64%±1.02% (group A), 12.94%±0.81% (group B), 37.19%±1.26% (group C), respectively. Group C showed a statistically greater amount of new bone formation compared with group A and group B (P<0.05). Conclusion: PRF mixed with BMAC couldaccelerate the regeneration of new bone to repair the rabbit calvarial defect.

Key words： platelet-rich fibrin bone marrow aspirate concentrate bone regeneration

收稿日期: 2017-08-07

基金资助:浙江省教育厅科研基金资助项目（Y201431637）。

作者简介: 杨颖（1987-），男，河南许昌人，住院医师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I5/375

[1] Dimitriou R, Mataliotakis G I, Angoules A G, et al. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review[J]. Injury, 2011, 42(2): S3-15.
[2] FINKEMEIER C G. Bone-grafting and bone-graft substi-tutes[J]. J Bone Joint Surg Am, 2002, 84-A(3): 454-464.
[3] COLNOT C, ROMERO D M, HUANG S, et al. Mechanisms of action of demineralized bone matrix in the repair of cortical bone defects[J]. Clin Orthop Relat Res, 2005(435): 69-78.
[4] BUCK B E, RESNICK L, SHAH S M, et al. Human immunodeficiency virus cultures from bone. Implications for transplantation[J]. Clin Orthop Relat Res, 1990(251): 249-253.
[5] SOLTAN M, SMILER D G, GAILANI F. A new “platinum” standard for bone grafting: autogenous stem cells[J]. Implant Dent, 2005, 14(4): 322-325.
[6] CHOUKROUN J, ADDA F, SCHOEFFLER C, et al. Une opportunité en paro-implantologie: le PRF[J]. Implantodontie, 2000, 42: 55-62.
[7] DOHAN E D M, LEMO N, JIMBO R, et al. Selecting a relevant animal model for testing the invivo effects of Choukroun’ s platelet-richfibrin (PRF): rabbit tricks and traps[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(4): 413-416.
[8] 丁俐丹, 胡赟, 唐世俊, 等. 富血小板纤维蛋白生物学特性鉴定及其对脂肪干细胞增殖和分化的影响[J]. 上海交通大学学报(医学版), 2017, 37(5): 601-605.
[9] DOHAN E D M, PINTO N R, PEREDA A, et al. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane [J]. Platelets, 2018, 29(2): 171-184.
[10] MADURANTAKAM P, YOGANARASIMHA S, HASAN
F K. Characterization of leukocyte-platelet rich fibrin, a novel biomaterial[J]. J Vis Exp, 2015, 103: e53221.
[11] QUARTO R, MASTROGIACOMO M, CANCEDDA R,
et al. Repair of large bone defects with the use of autologous bone marrow stromal cells[J]. N Engl J Med, 2001, 344(5): 385-386.
[12] MARCACCI M, KON E, MOUKHACHEV V, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study[J].Tissue Eng, 2007, 13(5): 947-955.
[13] LEE J, SUNG H M, JANG J D, et al. Successful reconstruction of 15-cm segmental defects by bone marrow stem cells and resected autogenous bone graft in central hemangioma [J]. J Oral Maxillofac Surg, 2010, 68(1): 188-194.
[14] HERNIGOU P, POIGNARD A, BEAUJEAN F, et al. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells [J]. J Bone Joint Surg Am, 2005, 87(7): 1430-1437
[15] CHANG F, ISHII T, YANAI T, et al. Repair of large full-thickness articular cartilage defects by transplantation of autologous uncultured bone-marrow-derived mononuclear cells[J]. J Orthop Res, 2008, 26(1): 18-26.
[16] HIGASHI Y, KIMURA M, HARA K, et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb isch-emia[J]. Circulation, 2004, 109(10): 1215-1218.
[17] UMEMURA T, NISHIOKA K, IGARASHI A, et al. Autologous bone marrow mononuclear cell implantation induces angiogenesis and bone regeneration in a patientwith compartment syndrome[J]. Circ J, 2006, 70(10): 1362-1364.
[18] 杨颖, 仲维剑, 刘国, 等. 自体骨髓浓缩物修复种植体周围的骨缺损[J]. 中国组织工程研究, 2014, 18(11): 1653-1658.
[19] OLIVEIRA M R, DeC SILVA A, FERREIRA S, et al. Influence of the association between platelet-rich fibrin and bovine bone on bone regeneration. A histomorphometric study in the calvaria of rats[J]. Int J Oral Maxillofac Surg, 2015, 44(5): 649-655.
[20] WU C C, SHEU S Y, HSU L H, et al. Intra-articular Injection of platelet-rich fibrin releasates in combination with bone marrow-derived mesenchymal stem cells in the treatment of articular cartilage defects: An in vivo study in rab-bits[J]. J Biomed Mater Res B Appl Biomater, 2017, 105(6): 1536-1543.
[21] DOHAN D M, CHOUKROUN J, DISS A, et al.Platelet-rich fibrin (PRF): a secondgeneration platelet concentrate. Part I: technological concepts and evolution[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006, 101(3): e37-e44.
[22] PICARDI A, LANTI A, CUDILLO L, et al. Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic humatopoietic stem cell trans-plant[J]. Transfusion, 2010, 50(2): 501-506.